| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 63 | 2023 | 67 | 5.660 |
Why?
|
| Autoantibodies | 78 | 2023 | 474 | 5.000 |
Why?
|
| Dermatomyositis | 55 | 2023 | 60 | 4.920 |
Why?
|
| Polymyositis | 23 | 2018 | 25 | 1.820 |
Why?
|
| Immunoprecipitation | 5 | 2020 | 68 | 1.790 |
Why?
|
| Blotting, Western | 6 | 2019 | 513 | 1.350 |
Why?
|
| Amino Acyl-tRNA Synthetases | 16 | 2021 | 19 | 1.270 |
Why?
|
| Proteins | 5 | 2019 | 252 | 1.270 |
Why?
|
| Autoimmune Diseases | 15 | 2022 | 164 | 1.160 |
Why?
|
| Autoantigens | 18 | 2013 | 212 | 1.150 |
Why?
|
| Antibodies, Antinuclear | 16 | 2020 | 183 | 1.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 2019 | 167 | 1.070 |
Why?
|
| Lung Diseases, Interstitial | 7 | 2021 | 19 | 0.830 |
Why?
|
| Scleroderma, Systemic | 11 | 2020 | 29 | 0.800 |
Why?
|
| Humans | 113 | 2023 | 28155 | 0.700 |
Why?
|
| Child | 25 | 2023 | 2249 | 0.490 |
Why?
|
| RNA, Transfer, Amino Acyl | 3 | 2007 | 5 | 0.440 |
Why?
|
| Aspartate-tRNA Ligase | 2 | 2007 | 2 | 0.430 |
Why?
|
| Male | 53 | 2021 | 13505 | 0.420 |
Why?
|
| Female | 57 | 2021 | 15183 | 0.410 |
Why?
|
| Antigens | 7 | 2006 | 67 | 0.410 |
Why?
|
| Adult | 42 | 2023 | 7764 | 0.390 |
Why?
|
| Antibody Specificity | 13 | 2006 | 114 | 0.390 |
Why?
|
| Glycine-tRNA Ligase | 5 | 1996 | 5 | 0.360 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 3 | 2021 | 11 | 0.360 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 454 | 0.340 |
Why?
|
| Arthritis | 3 | 2007 | 29 | 0.320 |
Why?
|
| DNA Helicases | 5 | 2006 | 52 | 0.310 |
Why?
|
| Calcinosis | 3 | 2019 | 25 | 0.300 |
Why?
|
| Epitopes | 7 | 2007 | 179 | 0.300 |
Why?
|
| Phenotype | 15 | 2022 | 679 | 0.300 |
Why?
|
| Pulmonary Fibrosis | 7 | 1996 | 15 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 75 | 0.290 |
Why?
|
| Ribonucleoproteins | 2 | 2019 | 154 | 0.290 |
Why?
|
| HLA-DR Antigens | 9 | 2009 | 29 | 0.290 |
Why?
|
| Nuclear Proteins | 5 | 2018 | 247 | 0.280 |
Why?
|
| Adenosine Triphosphatases | 4 | 2006 | 49 | 0.280 |
Why?
|
| Middle Aged | 28 | 2020 | 7164 | 0.280 |
Why?
|
| HLA-DR2 Antigen | 1 | 2007 | 3 | 0.270 |
Why?
|
| Environmental Exposure | 5 | 2016 | 48 | 0.270 |
Why?
|
| Adolescent | 19 | 2020 | 3126 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 677 | 0.250 |
Why?
|
| Sulfur Radioisotopes | 2 | 2019 | 10 | 0.250 |
Why?
|
| Exanthema | 3 | 2023 | 14 | 0.250 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2022 | 16 | 0.240 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 75 | 0.240 |
Why?
|
| Ultraviolet Rays | 3 | 2013 | 41 | 0.230 |
Why?
|
| Syndrome | 9 | 2014 | 78 | 0.230 |
Why?
|
| Isoleucine-tRNA Ligase | 3 | 1996 | 3 | 0.220 |
Why?
|
| Child, Preschool | 10 | 2021 | 1145 | 0.220 |
Why?
|
| Peptides | 1 | 2006 | 289 | 0.220 |
Why?
|
| Antibody Formation | 4 | 2002 | 77 | 0.210 |
Why?
|
| Glucocorticoids | 3 | 2021 | 115 | 0.210 |
Why?
|
| Sepharose | 2 | 2015 | 14 | 0.210 |
Why?
|
| Animals | 13 | 2019 | 10415 | 0.210 |
Why?
|
| Precipitin Tests | 10 | 1996 | 47 | 0.200 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 17 | 0.200 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2002 | 14 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2009 | 258 | 0.200 |
Why?
|
| Skin Ulcer | 1 | 2022 | 3 | 0.200 |
Why?
|
| Staphylococcal Protein A | 2 | 2015 | 3 | 0.200 |
Why?
|
| Antibodies | 4 | 1995 | 124 | 0.190 |
Why?
|
| Prednisone | 3 | 2018 | 54 | 0.180 |
Why?
|
| Methylprednisolone | 2 | 2018 | 15 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 148 | 0.180 |
Why?
|
| HeLa Cells | 6 | 2007 | 208 | 0.180 |
Why?
|
| Seasons | 4 | 2021 | 89 | 0.170 |
Why?
|
| SMN Complex Proteins | 1 | 2020 | 1 | 0.170 |
Why?
|
| Skin | 2 | 2019 | 148 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2013 | 991 | 0.160 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 372 | 0.160 |
Why?
|
| Interferons | 1 | 2020 | 69 | 0.160 |
Why?
|
| Ligases | 5 | 2008 | 18 | 0.160 |
Why?
|
| Histidine-tRNA Ligase | 5 | 2006 | 5 | 0.160 |
Why?
|
| Retrospective Studies | 9 | 2021 | 2557 | 0.160 |
Why?
|
| Risk Factors | 10 | 2022 | 2087 | 0.160 |
Why?
|
| Alanine-tRNA Ligase | 3 | 1998 | 3 | 0.150 |
Why?
|
| Collodion | 1 | 2019 | 19 | 0.150 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 1999 | 63 | 0.150 |
Why?
|
| Creatine Kinase | 4 | 2021 | 13 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 9 | 2022 | 33 | 0.150 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1996 | 16 | 0.150 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 13 | 0.140 |
Why?
|
| Antimalarials | 1 | 2018 | 25 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 451 | 0.140 |
Why?
|
| Molecular Weight | 4 | 2006 | 119 | 0.140 |
Why?
|
| HLA-DQ Antigens | 7 | 2006 | 25 | 0.140 |
Why?
|
| Acyl Coenzyme A | 1 | 2017 | 12 | 0.140 |
Why?
|
| Autoimmunity | 2 | 2020 | 156 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 86 | 0.130 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2017 | 16 | 0.130 |
Why?
|
| Aged | 10 | 2020 | 5416 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 81 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 153 | 0.130 |
Why?
|
| Molecular Sequence Data | 9 | 2009 | 1052 | 0.130 |
Why?
|
| Multienzyme Complexes | 2 | 1993 | 29 | 0.130 |
Why?
|
| Muscles | 3 | 1991 | 73 | 0.120 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 1995 | 1 | 0.120 |
Why?
|
| Tryptophan | 1 | 1995 | 38 | 0.120 |
Why?
|
| Logistic Models | 5 | 2020 | 407 | 0.120 |
Why?
|
| Biomarkers | 5 | 2017 | 763 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2015 | 25 | 0.120 |
Why?
|
| Nuclear Pore | 1 | 2014 | 1 | 0.120 |
Why?
|
| Polymorphism, Genetic | 3 | 2016 | 166 | 0.110 |
Why?
|
| Prolidase Deficiency | 1 | 2013 | 3 | 0.110 |
Why?
|
| Self Tolerance | 1 | 2013 | 9 | 0.110 |
Why?
|
| Muscular Dystrophies | 1 | 2013 | 4 | 0.110 |
Why?
|
| Prognosis | 7 | 2017 | 803 | 0.110 |
Why?
|
| Immunoglobulin Gm Allotypes | 4 | 2008 | 5 | 0.110 |
Why?
|
| Amino Acid Sequence | 6 | 2009 | 690 | 0.110 |
Why?
|
| HLA Antigens | 5 | 2006 | 57 | 0.110 |
Why?
|
| Signal Recognition Particle | 3 | 2008 | 3 | 0.110 |
Why?
|
| Young Adult | 5 | 2020 | 2737 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 329 | 0.100 |
Why?
|
| Age Factors | 3 | 2021 | 733 | 0.100 |
Why?
|
| RNA, Transfer | 4 | 1994 | 16 | 0.100 |
Why?
|
| Muscular Diseases | 1 | 1992 | 12 | 0.100 |
Why?
|
| Threonine-tRNA Ligase | 2 | 1992 | 2 | 0.100 |
Why?
|
| Immunoblotting | 4 | 2017 | 123 | 0.100 |
Why?
|
| Photofluorography | 1 | 2012 | 1 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 45 | 0.100 |
Why?
|
| Buffers | 1 | 2012 | 24 | 0.090 |
Why?
|
| Clinical Enzyme Tests | 2 | 1990 | 3 | 0.090 |
Why?
|
| Base Sequence | 5 | 1999 | 585 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2012 | 69 | 0.090 |
Why?
|
| Age of Onset | 4 | 2018 | 71 | 0.090 |
Why?
|
| Alleles | 6 | 2006 | 353 | 0.090 |
Why?
|
| Registries | 3 | 2021 | 386 | 0.090 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 3 | 1996 | 4 | 0.090 |
Why?
|
| Protein Sorting Signals | 1 | 1990 | 18 | 0.090 |
Why?
|
| Exoribonucleases | 3 | 1996 | 20 | 0.090 |
Why?
|
| Histocompatibility Testing | 3 | 2007 | 14 | 0.080 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 4 | 2006 | 13 | 0.080 |
Why?
|
| Antigen-Antibody Reactions | 4 | 1994 | 12 | 0.080 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2009 | 2 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 25 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2013 | 724 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 1015 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2008 | 1462 | 0.080 |
Why?
|
| Cell Nucleolus | 3 | 1994 | 26 | 0.080 |
Why?
|
| Haplotypes | 2 | 2007 | 283 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 300 | 0.080 |
Why?
|
| Immunoglobulin Km Allotypes | 1 | 2008 | 1 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 105 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2007 | 67 | 0.080 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 6 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2007 | 26 | 0.070 |
Why?
|
| Lipodystrophy | 1 | 2008 | 6 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 202 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2020 | 50 | 0.070 |
Why?
|
| African Americans | 2 | 2008 | 350 | 0.070 |
Why?
|
| Complement C4 | 2 | 2022 | 16 | 0.070 |
Why?
|
| Cytoplasm | 3 | 1993 | 57 | 0.070 |
Why?
|
| Immunodiffusion | 3 | 1999 | 12 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 2383 | 0.070 |
Why?
|
| Connective Tissue Diseases | 4 | 1997 | 13 | 0.070 |
Why?
|
| HLA-DQ alpha-Chains | 6 | 2006 | 8 | 0.060 |
Why?
|
| Sex Factors | 5 | 2013 | 465 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 367 | 0.060 |
Why?
|
| Immunogenetics | 2 | 2004 | 2 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 1996 | 20 | 0.060 |
Why?
|
| Antigens, Nuclear | 2 | 2013 | 22 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 66 | 0.060 |
Why?
|
| Mass Screening | 1 | 2006 | 152 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 634 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 1995 | 77 | 0.060 |
Why?
|
| United States | 6 | 2013 | 2150 | 0.060 |
Why?
|
| Chronic Disease | 3 | 2016 | 273 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2009 | 269 | 0.060 |
Why?
|
| Silicones | 1 | 2004 | 8 | 0.060 |
Why?
|
| Breast Implants | 1 | 2004 | 6 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 477 | 0.060 |
Why?
|
| Infant | 3 | 2018 | 1010 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 82 | 0.050 |
Why?
|
| Precipitins | 1 | 1983 | 1 | 0.050 |
Why?
|
| North America | 2 | 2021 | 40 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 1983 | 8 | 0.050 |
Why?
|
| Mice | 4 | 2008 | 4655 | 0.050 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 2021 | 0.050 |
Why?
|
| Complement C4a | 1 | 2022 | 3 | 0.050 |
Why?
|
| HLA-DR3 Antigen | 1 | 2022 | 10 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2023 | 56 | 0.050 |
Why?
|
| Escherichia coli | 2 | 1996 | 336 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 74 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 38 | 0.050 |
Why?
|
| Time Factors | 4 | 2010 | 1593 | 0.050 |
Why?
|
| DNA | 3 | 2009 | 374 | 0.050 |
Why?
|
| Liver | 3 | 1997 | 441 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 2 | 0.050 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2021 | 4 | 0.050 |
Why?
|
| Remission Induction | 1 | 2021 | 53 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2021 | 20 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1999 | 112 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 413 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 19 | 0.040 |
Why?
|
| Genes | 2 | 1990 | 36 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 281 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 81 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2020 | 4 | 0.040 |
Why?
|
| Endothelium | 1 | 2000 | 28 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 17 | 0.040 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 1999 | 1 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2009 | 969 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 68 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 62 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1999 | 132 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1996 | 131 | 0.040 |
Why?
|
| Disease Progression | 2 | 2017 | 474 | 0.040 |
Why?
|
| Arthritis, Juvenile | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 889 | 0.040 |
Why?
|
| Cell Nucleus | 3 | 1999 | 138 | 0.040 |
Why?
|
| Pedigree | 2 | 2013 | 155 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 61 | 0.040 |
Why?
|
| Biopsy | 3 | 1996 | 207 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 1997 | 20 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 494 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 207 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 414 | 0.030 |
Why?
|
| Binding Sites, Antibody | 2 | 1999 | 14 | 0.030 |
Why?
|
| Protozoan Proteins | 1 | 1997 | 52 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 2 | 2009 | 10 | 0.030 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 207 | 0.030 |
Why?
|
| Inclusion Bodies | 3 | 1993 | 7 | 0.030 |
Why?
|
| Immunoglobulin Fragments | 1 | 1996 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 7 | 0.030 |
Why?
|
| Lysine-tRNA Ligase | 1 | 1996 | 3 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 1995 | 23 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 54 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 193 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1995 | 13 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 1995 | 26 | 0.030 |
Why?
|
| Fasciitis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Oils | 1 | 1995 | 11 | 0.030 |
Why?
|
| Eosinophilia | 1 | 1995 | 8 | 0.030 |
Why?
|
| Genotype | 2 | 2009 | 457 | 0.030 |
Why?
|
| Rabbits | 1 | 1995 | 276 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 434 | 0.030 |
Why?
|
| Atrophy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 1989 | 270 | 0.030 |
Why?
|
| Peptide Elongation Factors | 1 | 1994 | 5 | 0.030 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 1994 | 6 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2018 | 522 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Amish | 1 | 2013 | 3 | 0.030 |
Why?
|
| Complement C1q | 1 | 2013 | 13 | 0.030 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 1994 | 41 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1994 | 29 | 0.030 |
Why?
|
| Precipitating Factors | 1 | 2013 | 4 | 0.030 |
Why?
|
| Epitope Mapping | 2 | 2007 | 38 | 0.030 |
Why?
|
| Azathioprine | 1 | 1993 | 6 | 0.030 |
Why?
|
| Methotrexate | 1 | 1993 | 34 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2000 | 521 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 633 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 210 | 0.030 |
Why?
|
| Amino Acids | 1 | 1993 | 84 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1992 | 21 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 145 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 24 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 1992 | 2 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 128 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1992 | 9 | 0.020 |
Why?
|
| Diclofenac | 1 | 1991 | 1 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 1991 | 1 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 2010 | 19 | 0.020 |
Why?
|
| Neural Conduction | 1 | 1990 | 26 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 12 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 27 | 0.020 |
Why?
|
| Myoglobin | 1 | 1990 | 33 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 657 | 0.020 |
Why?
|
| Immune System | 1 | 1989 | 29 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 1990 | 33 | 0.020 |
Why?
|
| Vimentin | 1 | 2009 | 28 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1989 | 39 | 0.020 |
Why?
|
| Mexico | 2 | 2002 | 88 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1989 | 36 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 163 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2009 | 34 | 0.020 |
Why?
|
| Electromyography | 1 | 1990 | 175 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1989 | 208 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 1992 | 263 | 0.020 |
Why?
|
| Myoglobinuria | 1 | 1988 | 2 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 190 | 0.020 |
Why?
|
| Acylation | 1 | 1988 | 10 | 0.020 |
Why?
|
| Threonine | 1 | 1988 | 20 | 0.020 |
Why?
|
| Acanthosis Nigricans | 1 | 2008 | 4 | 0.020 |
Why?
|
| Facial Dermatoses | 1 | 2008 | 3 | 0.020 |
Why?
|
| Contracture | 1 | 2008 | 4 | 0.020 |
Why?
|
| Hirsutism | 1 | 2008 | 18 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2008 | 15 | 0.020 |
Why?
|
| Panniculitis | 1 | 2008 | 4 | 0.020 |
Why?
|
| Creatine | 1 | 1988 | 32 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1988 | 72 | 0.020 |
Why?
|
| Rats | 2 | 1997 | 1568 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 237 | 0.020 |
Why?
|
| Muscular Atrophy | 1 | 2008 | 31 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 75 | 0.020 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 1987 | 1 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1987 | 12 | 0.020 |
Why?
|
| Parturition | 1 | 2007 | 17 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 124 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2008 | 58 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 36 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2010 | 1253 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2008 | 176 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2006 | 13 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2006 | 24 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 284 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2006 | 30 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 66 | 0.020 |
Why?
|
| Complement Fixation Tests | 1 | 1985 | 1 | 0.020 |
Why?
|
| Quebec | 1 | 2005 | 2 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2005 | 4 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 45 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 126 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2006 | 225 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1983 | 4 | 0.010 |
Why?
|
| Climate | 1 | 2003 | 33 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1983 | 21 | 0.010 |
Why?
|
| Global Health | 1 | 2003 | 51 | 0.010 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2002 | 1 | 0.010 |
Why?
|
| Indians, Central American | 1 | 2002 | 4 | 0.010 |
Why?
|
| Guatemala | 1 | 2002 | 30 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1983 | 134 | 0.010 |
Why?
|
| Neoplasms | 1 | 1991 | 818 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1999 | 14 | 0.010 |
Why?
|
| Korea | 1 | 1999 | 7 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1999 | 33 | 0.010 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 1998 | 24 | 0.010 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1998 | 2 | 0.010 |
Why?
|
| Myositis, Inclusion Body | 1 | 1998 | 2 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 71 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 200 | 0.010 |
Why?
|
| Thrombomodulin | 1 | 1997 | 10 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 18 | 0.010 |
Why?
|
| Poland | 1 | 1997 | 5 | 0.010 |
Why?
|
| Ku Autoantigen | 1 | 1997 | 12 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 36 | 0.010 |
Why?
|
| Ribonucleoprotein, U4-U6 Small Nuclear | 1 | 1996 | 1 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 315 | 0.010 |
Why?
|
| Isomerism | 1 | 1996 | 12 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 1996 | 14 | 0.010 |
Why?
|
| Japan | 1 | 1996 | 24 | 0.010 |
Why?
|
| Africa | 1 | 1996 | 16 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 8 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 27 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 75 | 0.010 |
Why?
|
| Centromere | 1 | 1995 | 39 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 1995 | 7 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1994 | 30 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 985 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 491 | 0.010 |
Why?
|
| Immunologic Tests | 1 | 1991 | 3 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 14 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1990 | 111 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1994 | 1573 | 0.000 |
Why?
|